Get access

Treatment of pediatric brain tumors

Authors

  • Matthias Karajannis,

    1. Department of Pediatrics, NYU School of Medicine, New York, New York
    2. NYU Cancer Institute and NYU Langone Medical Center, New York, New York
    Search for more papers by this author
  • Jeffrey C. Allen,

    1. NYU Cancer Institute and NYU Langone Medical Center, New York, New York
    2. Departments of Pediatrics and Neurology, NYU School of Medicine, New York, New York
    Search for more papers by this author
  • Elizabeth W. Newcomb

    Corresponding author
    1. NYU Cancer Institute and NYU Langone Medical Center, New York, New York
    2. Department of Pathology, NYU School of Medicine, New York, New York
    • Department of Pathology, NYU School of Medicine and NYU Langone Medical Center, MSB128, 550 First Avenue, New York, NY.
    Search for more papers by this author

Abstract

Over the past decades considerable advances have been made in neurosurgery, radiotherapy and chemotherapy resulting in improved survival and cure rates for children with brain tumors. Here we review four of the most common subtypes of pediatric brain tumors, low-grade and high-grade astrocytomas, medulloblastomas and ependymomas, highlighting their molecular features regarding their tumor biology, and promising potential therapeutic targets that may hold promise for finding new “molecular targeted” drugs. Importantly, appropriate clinical trial design will play a critical role in the evaluation of new and novel treatment approaches for pediatric brain tumors. J. Cell. Physiol. 217: 584–589, 2008. © 2008 Wiley-Liss, Inc.

Get access to the full text of this article

Ancillary